.Attributes Medication, Published online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint calls for addition of individuals along with MASLD as well as dimension of liver outcomes in cardio-- kidney-- metabolic trials, when information propose mechanistically tenable perks and also scientific safety and security-- as well as details considerations for trial style and governing commendation.